Please assess the completion status of the following clinical trial:

Trial Title: Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes mellitus~* Patient is not pregnant or breastfeeding~* Male or female patient unlikely to conceive~* Patient not on an antihyperglycemic drug~Exclusion Criteria:~* Patient has history of type 1 diabetes mellitus~* Patient has history of ketoacidosis~* Patient requires insulin within 8 weeks prior to start of study~* Patient on weight loss program and is not in maintenance phase~* Patient taking weight loss medication within 8 weeks prior to start of study~* Patient on or likely to require = 14 days or repeated courses of corticosteroids~* Patient taking immunosuppressive/immunomodulating medication~* Patient taking digoxin or other cardiac medication~* Patient has undergone surgical general anesthesia within 30 days prior to start of study~* Patient taking investigational drug within 8 weeks prior to start of study~* Patient is diagnosed with liver disease~* Patient has chronic myopathy, progressive neurological/neuromuscular disorder~* Patient has with severe cardiac conditions within the last 6 months~* Patient is Human immunodeficiency virus (HIV) positive~* Patient has hematological disorder~* Patient has history of malignancy~* Patient has history of alcohol or drug abuse within the past 3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin 100 mg/100 mg (Type: ACTIVE_COMPARATOR): Phase A and B: Oral tablets of sitagliptin 100 mg Once a Day (q.d )
- Sitagliptin 200 mg/200 mg (Type: ACTIVE_COMPARATOR): Phase A and B: Oral tablets of sitagliptin 200 mg q.d
- Placebo/Sitagliptin 100 mg (Type: PLACEBO_COMPARATOR): Phase A: Oral tablets of placebo matching sitagliptin 100 mg q.d. Phase B: Oral tablets of sitagliptin 100 mg q.d.
- Placebo/Sitagliptin 200 mg (Type: PLACEBO_COMPARATOR): Phase A: Oral tablets of placebo matching sitagliptin 200 mg q.d. Phase B: Oral tablets of sitagliptin 200 mg q.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).